Free shipping on all orders over $ 500

WZ4002

Cat. No. M1850
WZ4002 Structure
Synonym:

WZ-4002

Size Price Availability Quantity
Free Sample (0.5-1 mg)  USD 0 In stock
5mg USD 50  USD50 In stock
10mg USD 80  USD80 In stock
50mg USD 200  USD200 In stock
100mg USD 360  USD360 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

WZ4002 is a novel, selective EGFR kinase inhibitor against EGFR T790M (mutation of the gatekeeper T790 residue) with IC50 of 8 nM. This agent is 30- to 100-fold more potent against EGFR T790M, and up to 100-fold less potent against wildtype EGFR, than quinazoline-based EGFR inhibitors (HKI-272 and CL-387,785) in vitro. WZ4002 inhibits EGFR, AKT and ERK1/2 phosphorylation in NSCLC cell lines and WZ4002 prevents of EGFR phosphorylation in NIH-3T3 cells expressing different EGFR T790M mutant alleles. In addition, the phosphorylated EGFR of Src TKI-resistant H1975 cells, as well as HCC827 cells, is completely suppressed by the third generation EGFR TKI, WZ4002. In a 2-week efficacy study, WZ4002 treatment resulted in significant tumour regressions compared with vehicle alone in both T790M-containing murine models.

Product Citations
Customer Product Validations & Biological Datas
Source Clin Cancer Res (2017). Figure 4. WZ4002 (Abmole Bioscience)
Method vitro observations
Cell Lines Mice harboring H1975 ER-TWIST+4-OHT tumors
Concentrations 25mg/kg
Incubation Time 5 d
Results "Consistent with our in vitro observations, while single-agent WZ4002 was sufficient to markedly slow the growth of the tumors, the addition of ABT-263 was necessary to shrink tumors (Fig. 4D)."
Source Clin Cancer Res (2017). Figure 3. WZ4002 (Abmole Bioscience)
Method Western blotting
Cell Lines H1975 parental cells (par), H1975 R1 cells (R1), and H1975 R2 cells (R2)
Concentrations 1 μM
Incubation Time 72 h
Results Similarly, in the H1975 EMT model induced by ER-TWIST, knockdown of ZEB1 led to de-repression of BIM protein and RNA (Fig. 3I and Sup. Fig. 5B, right panel) and restored EGFRi-induced apoptosis and re-sensitized these EMT cancers to WZ4002 (Fig. 3J and 3K).
Source Clin Cancer Res (2017). Figure 2. WZ4002 (Abmole Bioscience)
Method apoptosis quantified
Cell Lines HCC4006 and H1975 cells
Concentrations 1 μM
Incubation Time 72 h
Results We found directly inducing EMT by exogenous TWIST activation (Fig. 2) or chronic TGF- β treatment (Sup. Fig. 2) led to depressed levels of BIM resulting in suppression of EGFRi-induced apoptosis and resistance to EGFRi (WZ4002 and gefitinib).
Protocol (for reference only)
Cell Experiment
Cell lines NSCLC or Ba/F3 cells
Preparation method Cell proliferation and growth assays
NSCLC or Ba/F3 cells were exposed to treatment for 72 hours and the number of cells used per experiment determined empirically and has been previously established2,7. All experimental points were set up in six to twelve wells and all experiments were repeated at least three times. The data was graphically displayed using GraphPad Prism version 5.0 for Windows, (GraphPad Software; www.graphpad.com). The curves were fitted using a non-linear regression model with a sigmoidal dose response.
Concentrations 0~10 μM
Incubation time 72 h
Animal Experiment
Animal models EGFR-TL (T790M/L858R) mice and EGFR exon19 Deletion-T790M (TD) inducible bitransgenic mice
Formulation NMP (10% 1-methyl-2-pyrrolidinone: 90% PEG-300)
Dosages 25mg/kg daily
Administration gavage
Chemical Information
Molecular Weight 494.97
Formula C25H27ClN6O3
CAS Number 1213269-23-8
Solubility (25°C) DMSO ≥12 mg/mL
Storage Powder          -20°C   3 years ;  4°C   2 years
In solvent       -80°C   6 months ;  -20°C   1 month
Conversion of different model animals based on BSA (PMID: 27057123)
Species Mouse Rat Rabbit Guinea pig Hamster Dog
Weight (kg) 0.02 0.15 1.8 0.4 0.08 10
Body Surface Area (m2) 0.007 0.025 0.15 0.05 0.02 0.5
Km factor 3 6 12 8 5 20
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.

References

[1] Nakagawa et al. Mol Cancer Ther. Combined therapy with mutant-selective EGFR inhibitor and Met kinase inhibitor for overcoming erlotinib resistance in EGFR mutant lung cancer.

[2] Sakuma et al. Biochem Biophys Res Commun. NF-κB signaling is activated and confers resistance to apoptosis in three-dimensionally cultured EGFR-mutant lung adenocarcinoma cells.

[3] Sakuma et al. Lab Invest. WZ4002, a third-generation EGFR inhibitor, can overcome anoikis resistance in EGFR-mutant lung adenocarcinomas more efficiently than Src inhibitors.

[4] Zhou W, et al. Nature. Novel mutant-selective EGFR kinase inhibitors against EGFR T790M.

Related EGFR/HER2 Products
BBT-207

BBT-207 is a reversible, mutant-specific EGFR inhibitor with antitumor activity.

VRN-11

VRN-11 is an EGFR C797S inhibitor.

TRX-221

TRX-221 is an EGFR C797S inhibitor.

TAS-3351

TAS-3351 is an EGFR C797S inhibitor.

Larotinib mesylate hydrate

Larotinib mesylate hydrate is a potent, broad-spectrum, orally active tyrosine kinase inhibitor (TKI) that primarily targets EGFR with an IC50 of 0.6 nM.

  Catalog
Abmole Inhibitor Catalog




Keywords: WZ4002, WZ-4002 supplier, EGFR/HER2, inhibitors, activators


Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.